نظارت و درمان پوکی استخوان
Abstract
1- Background
2- Screening and Diagnosis
3- Management of Osteoporosis and Osteopenia
4- Conclusion
References
Abstract
Osteoporosis and poor bone health effects approximately 200 million people worldwide, with numbers expected to increase as the population ages. Increases in osteoporosis and poor bone health are associated with increased fragility fracture rates, increased morbidity and mortality, and a huge economic burden. Osteoporosis screening and treatment guideline recommendations are currently underutilized resulting in a public health concern. This article describes current osteoporosis screening recommendations, pharmacological interventions, and a collaborative approach to treatment.
Background
Osteoporosis is the most common human bone disease.4 An estimated 10.2 million Americans are living with osteoporosis and 43.4 million more Americans have low bone density, which accounts for 54% of the over-age-50 population. The US prevalence of osteoporosis and osteopenia combined is 35.5 million in women and 18.2 million in men. Osteoporosis and osteoporotic fragility fractures are a growing concern worldwide and are expected to increase with the aging population,1 with an estimated increase of 10.4 million (19%) by 2020 and 17.2 million (32%) by 2030.2 Approximately 50% of Caucasian females and 20% of males will experience an osteoporotic-related fracture of the hip, wrist, or spine in their lifetime.4,5 Although the number of men with osteoporosis is lower than the number of women with the disease, the incidence of fractures in males with osteoporosis is higher than the risk of fracture in women with osteoporosis,6 at least partially owing to gender inequalities in testing and treatment.